Psychedelics research company Champignon Brands SHRM SHRMF announced Friday it is acquiring AltMed Capital Corp.
Run by Dr. Roger McIntyre, AltMed has been operating a ketamine clinic, the Health Canada-approved Canadian Rapid Treatment Centre of Excellence (CRTCE), for more than 18 months now.
Dr. McIntyre is well known in his field, having published more than 600 articles. AltMed’s director, Pat McCutcheon, is the co-founder and CEO of MediPharm Labs LABS MEDIF.
Chatting with Benzinga, Dr. McIntyre said, "Our new corporation is the largest and most influential company in the world that integrates both research and development of ketamine and psychedelic medicines along with excellence in the multidisciplinary care of persons with mood and related disorders (e.g. PTSD, pain substance abuse)."
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.